Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Microscopic colitis or functional bowel disease with diarrhea: a French prospective multicenter study.
Macaigne G, Lahmek P, Locher C, Lesgourgues B, Costes L, Nicolas MP, Courillon-Mallet A, Ghilain JM, Bellaïche G, de Montigny-Lehnardt S, Barjonet G, Vitte RL, Faroux R, Lambare B, Fleury A, Pariente A, Nahon S. Macaigne G, et al. Among authors: courillon mallet a. Am J Gastroenterol. 2014 Sep;109(9):1461-70. doi: 10.1038/ajg.2014.182. Epub 2014 Jul 8. Am J Gastroenterol. 2014. PMID: 25001258
Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake.
Charpignon C, Lesgourgues B, Pariente A, Nahon S, Pelaquier A, Gatineau-Sailliant G, Roucayrol AM, Courillon-Mallet A; Group de l'Observatoire National des Ulcères de l'Association Nationale des HépatoGastroentérologues des Hôpitaux Généraux (ANGH). Charpignon C, et al. Among authors: courillon mallet a. Aliment Pharmacol Ther. 2013 Oct;38(8):946-54. doi: 10.1111/apt.12465. Epub 2013 Aug 27. Aliment Pharmacol Ther. 2013. PMID: 23981105 Free article.
Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg).
Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Kupcinskas J, Jonaitis L, Bujanda L, Lucendo A, Jurecic NB, Perez-Lasala J, Shvets O, Fadeenko G, Huguet JM, Kikec Z, Bordin D, Voynovan I, Leja M, Machado JC, Areia M, Fernandez-Salazar L, Rodrigo L, Alekseenko S, Barrio J, Ortuño J, Perona M, Vologzhanina L, Romero PM, Zaytsev O, Rokkas T, Georgopoulos S, Pellicano R, Buzas GM, Modolell I, Gomez Rodriguez BJ, Simsek I, Simsek C, Lafuente MR, Ilchishina T, Camarero JG, Dominguez-Cajal M, Ntouli V, Dekhnich NN, Phull P, Nuñez O, Lerang F, Venerito M, Heluwaert F, Tonkic A, Caldas M, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Nyssen OP, et al. Am J Gastroenterol. 2021 Jun 1;116(6):1220-1229. doi: 10.14309/ajg.0000000000001246. Am J Gastroenterol. 2021. PMID: 33840725
Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies.
Lamouliatte H, Mégraud F, Delchier JC, Bretagne JF, Courillon-Mallet A, De Korwin JD, Fauchère JL, Labigne A, Fléjou JF, Barthelemy P; Multicentre Study Group. Lamouliatte H, et al. Aliment Pharmacol Ther. 2003 Oct 15;18(8):791-7. doi: 10.1046/j.1365-2036.2003.01759.x. Aliment Pharmacol Ther. 2003. PMID: 14535872 Free article. Clinical Trial.
39 results